Business Wire

PureTech Founded Entity Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx ® for Pediatric ADHD Patients in ...

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with ...
Nasdaq

Akili Integrates First-of-its-Kind Prescription Video Game Treatment with the Virtual World Through Partnership with Roblox

The Roblox vision for bringing people together through shared experiences, plus the Akili commitment to a new era of cognitive medicine, make the companies ideal partners to deliver a reimagined ...
Seeking Alpha

Virtual Therapeutics, Akili Interactive Enter Into Definitive Merger Agreement to Establish Leading Digital Health Company

KIRKLAND, Wash. & BOSTON--(BUSINESS WIRE)-- Virtual Therapeutics, a company focused on improving mental health at scale using engaging, immersive games, and Akili, Inc., a leading digital therapeutics ...
VentureBeat

Akili to Participate in the Cowen 43rd Annual Health Care Conference

Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, will participate in the Cowen 43 rd Annual Health Care Conference in Boston next month. On March 8, Akili sessions are scheduled for the ...
VentureBeat

Akili Interactive, a Leader in Digital Medicine, to Become Publicly Traded Through Combination with Social Capital Suvretta Holdings Corp. I

Akili Interactive (“Akili” or the “Company”), a leading digital medicine company developing cognitive treatments through game-changing technologies, has entered into a definitive agreement to become ...
MobiHealthNews

Akili, University of California's new licensing agreement marries physical activity with digital cognitive dysfunction therapy

Digital therapeutics maker Akili Interactive Labs today announced a deal with the University of California’s governing board concerning exclusive licensing of a new technology that will combine the ...
Nasdaq

Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx® for Pediatric ADHD Patients in Japan

BOSTON--(BUSINESS WIRE)-- Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today announced that its Japanese partner Shionogi & Co. Ltd has submitted Akili’s digital therapeutic SDT-001 ...